186 related articles for article (PubMed ID: 32583907)
1. Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.
Hamatani T; Fukudo S; Nakada Y; Inada H; Kazumori K; Miwa H
Aliment Pharmacol Ther; 2020 Aug; 52(3):430-441. PubMed ID: 32583907
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of 5-HT4 Receptor Agonist Minesapride for Irritable Bowel Syndrome with Constipation in a Randomized Controlled Trial.
Fukudo S; Nakamura M; Hamatani T; Kazumori K; Miwa H
Clin Gastroenterol Hepatol; 2021 Mar; 19(3):538-546.e8. PubMed ID: 32184185
[TBL] [Abstract][Full Text] [Related]
3. Thorough QT/QTc Study Shows That a Novel 5-HT
Hamatani T; Noda N; Takagaki T; Yodo Y; Kawai H; Kakuyama H; Kaji Y; Fujio Y
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):938-951. PubMed ID: 32087003
[TBL] [Abstract][Full Text] [Related]
4. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
Chey WD; Lembo AJ; Rosenbaum DP
Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495
[TBL] [Abstract][Full Text] [Related]
5. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
Fukudo S; Nakajima A; Fujiyama Y; Kosako M; Nakagawa A; Akiho H; Nakashima Y; Johnston JM; Miwa H
Neurogastroenterol Motil; 2018 May; 30(5):e13275. PubMed ID: 29278278
[TBL] [Abstract][Full Text] [Related]
6. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
Brenner DM; Fogel R; Dorn SD; Krause R; Eng P; Kirshoff R; Nguyen A; Crozier RA; Magnus L; Griffin PH
Am J Gastroenterol; 2018 May; 113(5):735-745. PubMed ID: 29545635
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan.
Fukudo S; Miwa H; Nakajima A; Haruma K; Kosako M; Nakagawa A; Akiho H; Yamaguchi Y; Johnston JM; Currie M; Kinoshita Y
Neurogastroenterol Motil; 2018 Dec; 30(12):e13444. PubMed ID: 30136447
[TBL] [Abstract][Full Text] [Related]
9. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
10. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
Tegaserod Clinical Research Group
Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
[TBL] [Abstract][Full Text] [Related]
11. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
[TBL] [Abstract][Full Text] [Related]
12. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.
Tack JF; Miner PB; Fischer L; Harris MS
Aliment Pharmacol Ther; 2011 Oct; 34(8):868-77. PubMed ID: 21883322
[TBL] [Abstract][Full Text] [Related]
13. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
Rao S; Lembo AJ; Shiff SJ; Lavins BJ; Currie MG; Jia XD; Shi K; MacDougall JE; Shao JZ; Eng P; Fox SM; Schneier HA; Kurtz CB; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1714-24; quiz p.1725. PubMed ID: 22986440
[TBL] [Abstract][Full Text] [Related]
14. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, safety and metabolite profiling of minesapride, a novel 5-HT
Hamatani T; Shibue Y; Sawada N; Takagaki T; Hashimoto M; Nakada Y; Kakuyama H
Drug Metab Pharmacokinet; 2020 Dec; 35(6):563-570. PubMed ID: 33189559
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial.
Lacy BE; King J; Shortino D; Schaumburg C; Haag-Molkenteller C; Chey WD
Neurogastroenterol Motil; 2022 Dec; 34(12):e14448. PubMed ID: 35975404
[TBL] [Abstract][Full Text] [Related]
17. Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.
Chang L; Chey WD; Drossman D; Losch-Beridon T; Wang M; Lichtlen P; Mareya S
Aliment Pharmacol Ther; 2016 Nov; 44(10):1114-1122. PubMed ID: 27669680
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1).
Chey WD; Lembo AJ; Rosenbaum DP
Am J Gastroenterol; 2020 Feb; 115(2):281-293. PubMed ID: 31934897
[TBL] [Abstract][Full Text] [Related]
19. Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study.
Fukudo S; Miwa H; Nakajima A; Kinoshita Y; Kosako M; Nakagawa A; Akiho H; Kuroishi K; Johnston JM; Currie M; Ohkusa T
Neurogastroenterol Motil; 2018 Dec; 30(12):e13442. PubMed ID: 30084233
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome.
Chapman RW; Stanghellini V; Geraint M; Halphen M
Am J Gastroenterol; 2013 Sep; 108(9):1508-15. PubMed ID: 23835436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
